6OpenAI Release Notes·
OpenAI launches ChatGPT for Clinicians, a free verified-clinician workspace in the US
OpenAI is launching ChatGPT for Clinicians, a free, dedicated workspace for verified US clinicians accessible under an existing ChatGPT account. The product targets point-of-care use cases including evidence review, clinical documentation, medical literature research, and CME credit support. It includes trusted clinical search, citations, and reusable skills. This marks OpenAI's first explicit product targeting licensed healthcare professionals at the point of care.
Related guides (3)
Related events (8)
Making ChatGPT Better for Clinicians
OpenAI is making ChatGPT for Clinicians free for verified U.S. physicians, nurse practitioners, and pharmacists. The offering targets clinical care, documentation, and research workflows. This represents a targeted enterprise deployment move into the healthcare vertical.
Introducing ChatGPT Health
OpenAI has launched ChatGPT Health, a dedicated product experience designed to integrate personal health data and third-party health apps into ChatGPT. The product features privacy protections and a physician-informed design, positioning OpenAI as a direct player in the consumer health AI space. This represents a significant vertical expansion of ChatGPT beyond general-purpose assistance.
OpenAI launches Health space in ChatGPT with medical records and Apple Health integration
OpenAI is rolling out a dedicated Health space within ChatGPT that allows users to connect medical records, Apple Health, and wellness apps to ground responses in personal health data. Health conversations and files are kept separate from the rest of ChatGPT and are not used to train foundation models. The feature launches on web and iOS for Free, Go, Plus, and Pro users in supported countries, excluding the EEA, Switzerland, and the UK, with a waitlist for early access.
OpenAI deploys GPT-5.5 Instant to improve ChatGPT health and wellness responses
OpenAI has updated ChatGPT's health and wellness capabilities using GPT-5.5 Instant, citing improvements in reasoning, contextual understanding, and communication clarity. The update was informed by physician evaluations, suggesting a structured clinical validation process. This represents both a model deployment signal and a domain-specific capability push into health intelligence.
OpenAI Launches ChatGPT Edu for Universities
OpenAI announced ChatGPT Edu, an affordable tier of ChatGPT designed specifically for university deployment. The offering aims to help higher education institutions responsibly integrate AI into campus life. This is a product launch targeting the academic sector with pricing and governance features suited for institutional use.
OpenAI begins testing ads in ChatGPT for Free and Go tier users in the U.S.
OpenAI is rolling out an ad test in ChatGPT for logged-in adult users on Free and Go tiers in the United States, with paid plans (Plus, Pro, Business, Enterprise, Education) remaining ad-free. Ads are clearly labeled, visually separated from answers, and personalized using in-session data that is not shared with advertisers. The system excludes ads from sensitive topics (health, mental health, politics) and users predicted to be under 18, with user controls for dismissal and data deletion.
Introducing ChatGPT Pro
OpenAI announced ChatGPT Pro, a new subscription tier aimed at broadening access to frontier AI capabilities. The announcement comes from OpenAI's official blog and signals a product and pricing strategy move to expand usage of their most advanced models. Details on specific model access, pricing, and feature differentiation were not included in the provided body text.
OpenAI Improves ChatGPT Mental Health Responses with Expert Collaboration
OpenAI worked with over 170 mental health experts to enhance ChatGPT's handling of sensitive conversations involving distress. The update improves the model's ability to recognize emotional distress, respond with empathy, and direct users to real-world support resources. OpenAI reports a reduction in unsafe responses of up to 80% as a result of these changes.